ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership

from Applied Clinical Trials · host Applied Clinical Trials

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & Johnson’s positive Phase IIb results for nipocalimab in systemic lupus erythematosus, and break down a new multibillion-dollar research and licensing agreement between Nimbus Therapeutics and Eli Lilly targeting oral obesity treatments.

Episode metadata supplied by the publisher feed · Published Jan 7, 2026

Embed this episode

Attribution link and audio player

Ready to play

ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership

0:00 2:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Applied Clinical Trials?

This episode is 2 minutes long.

When was this Applied Clinical Trials episode published?

This episode was published on January 7, 2026.

Can I download this Applied Clinical Trials episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!